David Hirst

Title: David Hirst: Innovator in Cancer Research

Introduction

David Hirst is a notable inventor based in Belfast, GB. He has made significant contributions to the field of cancer research, particularly in the development of assay methods and therapeutic peptides. With a total of 4 patents, Hirst's work focuses on improving treatment options for hormone-responsive cancers.

Latest Patents

Hirst's latest patents include innovative methods and compositions aimed at enhancing cancer treatment. One of his key patents is titled "Assay methods for the determination of FKBPL expression level in the context of breast cancer." This patent discloses methods that utilize FKBPL as a marker for a subject's sensitivity to endocrine therapies in cancer treatment. It also serves as a predictive marker for cancer progression and disease-free survival in hormone-responsive cancers. Another significant patent is "Peptides, compositions and uses thereof," which describes an N-terminal hexapeptide fragment of maximakinin, QUB 698.8. This peptide exhibits potent tissue-selective actions on smooth muscle, demonstrating a high degree of selectivity for arterial smooth muscle over small intestinal smooth muscle. It has potential applications in treating cardiovascular diseases and promoting angiogenesis.

Career Highlights

Throughout his career, David Hirst has worked with esteemed organizations such as The Queen's University of Belfast and Almac Group Limited. His research has contributed to advancements in cancer therapies and has positioned him as a key figure in the field.

Collaborations

Hirst has collaborated with notable colleagues, including Tianbao Chen and Martin O'Rourke. These partnerships have further enriched his research and innovation efforts.

Conclusion

David Hirst's contributions to cancer research through his patents and collaborations highlight his commitment to improving treatment options for patients. His innovative work continues to pave the way for advancements in the medical field.